ALIROCUMAB

Brand name:

• Praluent®

Pharmaceutical company:

Sanofi-aventis Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Hypercholesterolaemia

PBAC Submission type:

Change to recommended listing (Minor)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2020

Related medicines:

--

Submission received for:

March 2020 PBAC meeting

Opportunity for consumer comment:

Open 24/12/2019 and close 12/02/2020 (see PBS Website)

PBAC meeting:

Held on 11/03/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

09/10/2020

Lodgement of required documentation:

28/10/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 03/12/2020

Status:

Finalised

Government processes:

Commenced on 01/06/2021

Medicine listed on the PBS:

01/08/2021 (see PBS schedule)

---